Tuesday, July 1, 2025 7/1/2025

Carbapenemase-Stable Carbapenem Antibiotics for Treatment of Multidrug-Resistant Acinetobacter baumannii Infections

Award Number: R01AI155723
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 04/06/2021
PERIOD OF PERFORMANCE END DATE: 03/31/2026

Group Awards By:

View Award Description

Carbapenemase-Stable Carbapenem Antibiotics for Treatment of Multidrug-Resistant Acinetobacter baumannii Infections - Acinetobacter baumannii is listed by the CDC as a clinical pathogen that poses a serious antibiotic resistance threat in the United States, due to its resistance to the last resort carbapenem antibiotics (carbapenem-resistant A. baumannii or CRAb), which were the drugs of choice for treatment of infections caused by this microorganism. In addition, CRAb is often resistant to antimicrobial agents of different classes (multi-drug-resistant A. baumannii or MDRAb), which severely limits available therapeutic options. The major mechanism of resistance of A. baumannii to carbapenems is production of antibiotic-inactivating enzymes, carbapenem-hydrolyzing class D β- lactamases or CHDLs. In addition, carbapenemases of classes A and B, sensitivity of carbapenem targets (bacterial penicillin-binding proteins or PBPs), rates of antibiotic penetration into the bacterial cell and their expulsion by efflux pumps can also contribute to resistance. Levels of resistance to carbapenems reach up to 90% in some parts of the world, and mortality rates from infections caused by such bacteria are staggeringly high, up to 50%. Our long-term goal is to develop novel antibiotics for treatment of deadly MDRAb infections. Over the last decade, the Vakulenko group has performed in-depth characterization of clinically important CHDLs, which provides guidance for development of a new generation of carbapenems capable of inhibiting these enzymes. Concurrently, Dr. John Buynak’s (co-PI) group developed dozens of novel atypically-modified carbapenem antibiotics. We evaluated these antibiotics for their activity against MDRAb and demonstrated that three of them possess superior activity (when compared to commercial carbapenems) against MDRAb. All three inhibited the most prevalent A. baumannii CHDL, OXA-23, and had varying spectra of inhibitory activity against other CHDLs and carbapenemases of other classes. One of these compounds had an unprecedented wide spectrum of activity and resisted hydrolysis by a wide range of clinically important carbapenemases of all molecular classes. In this grant application, we propose to perform detailed characterization of our novel carbapenem antibiotics. We will determine activity of our compounds against A. baumannii strains expressing major CHDLs and other carbapenemases and unveil kinetic and structural features responsible for their ability to inhibit these enzymes (Aim 1). We will study interaction of our novel carbapenems with their targets, PBPs, and determine to what extent efflux pumps and porins influence bacterial resistance to these antibiotics (Aim 2). We will design and characterize several dozen novel carbapenem antibiotics to further improve their antimicrobial activity by enhancing their inhibitory potency against various carbapenemases, improving affinity for PBPs and increasing penetration rates and resistance to efflux (Aim 3). We will perform in vitro characterization of our best novel carbapenems to assess their solubility, stability and toxicity. Finally, our best compounds will be evaluated in animal studies to appreciate their potential as novel therapeutic agents against MDRAb (Aim 4).


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $773,298 )
2025	2025	UNIVERSITY OF NOTRE DAME DU LAC	940 GRACE HALL	NOTRE DAME	IN	46556	ST JOSEPH	USA	Allergy and Infectious Diseases Research	000	5	3/19/2025	NON-COMPETING CONTINUATION	$773,298
														Subtotal = $773,298

Issue Date FY: 2024 ( Subtotal = $773,298 )
2024	2024	UNIVERSITY OF NOTRE DAME DU LAC	836 GRACE HALL	NOTRE DAME	IN	46556	ST JOSEPH	USA	Allergy and Infectious Diseases Research	000	4	4/1/2024	NON-COMPETING CONTINUATION	$773,298
														Subtotal = $773,298

Issue Date FY: 2023 ( Subtotal = $773,298 )
2023	2023	UNIVERSITY OF NOTRE DAME DU LAC	940 GRACE HALL	NOTRE DAME	IN	46556	ST JOSEPH	USA	Allergy and Infectious Diseases Research	000	3	3/7/2023	NON-COMPETING CONTINUATION	$773,298
														Subtotal = $773,298

Issue Date FY: 2022 ( Subtotal = $773,154 )
2022	2022	UNIVERSITY OF NOTRE DAME DU LAC	940 GRACE HALL	NOTRE DAME	IN	46556	ST JOSEPH	USA	Allergy and Infectious Diseases Research	000	2	3/2/2022	NON-COMPETING CONTINUATION	$773,154
														Subtotal = $773,154

Issue Date FY: 2021 ( Subtotal = $784,115 )
2021	2021	UNIVERSITY OF NOTRE DAME DU LAC	940 GRACE HALL	NOTRE DAME	IN	46556	ST JOSEPH	USA	Allergy and Infectious Diseases Research	000	1	4/6/2021	NEW	$784,115
														Subtotal = $784,115

Grand Total All Awards = $3,877,163

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Carbapenemase-Stable Carbapenem Antibiotics for Treatment of Multidrug-Resistant Acinetobacter baumannii Infections

Award Number: R01AI155723

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 04/06/2021

PERIOD OF PERFORMANCE END DATE: 03/31/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer